Keywords: UK, NICE, Roche, Avastin, Herceptin, GlaxoSmithKline, Tyverb, Breast cancer, Colorectal cancer

More NICE rejections, for Roche’s Avastin and Herceptin and GlaxoSmithKline’s Tyverb

Article | 15 December 2010

Print This

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued final guidance to the National Health ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in